Try our beta test site
150 studies found for:    johnstown
Show Display Options
Rank Status Study
1 Completed Comparative Study Between Continuous Epidural Anesthesia And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter
Condition: Anesthesia; Adverse Effect, Spinal and Epidural
Interventions: Device: Epidural (B. Braun);   Device: Spinal (Wiley Spinal Catheter)
2 Withdrawn Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction
Condition: Macromastia (Symptomatic)
Interventions: Device: PEAK PlasmaBlade;   Procedure: Scalpel and Traditional Electrosurgery
3 Completed The Effects of Vitamin D and Bone Loss in Parkinson's Disease
Condition: Parkinson Disease
Interventions: Dietary Supplement: Vitamin D3;   Other: Placebo
4 Completed Set Point Acupuncture for Migraines Using a Digital Assistant
Condition: Migraine Headaches
Intervention: Procedure: acupuncture
5 Terminated Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery
Condition: Pain
Intervention: Procedure: Thoracic Paravertebral Nerve Block
6 Completed Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
Condition: Charcot Marie Tooth Disease
Interventions: Drug: Coenzyme Q10;   Dietary Supplement: Coenzyme Q10
7 Terminated Sedation Versus No Sedation in a Spontaneous Breathing Trial
Condition: Respiratory Insufficiency
Interventions: Other: Sedation during SBT;   Other: No sedation
8 Terminated A Prospective, Randomized Trial of Early Versus Late Tracheostomy in Trauma Patients With Severe Brain Injury
Conditions: Respiratory Failure;   Traumatic Brain Injury
Interventions: Procedure: Early tracheostomy;   Procedure: Late tracheostomy
9 Completed Financial and Clinical Impact of Repeal of the Pennsylvania Motorcycle Helmet Law
Conditions: Craniocerebral Trauma;   Facial Injuries
Intervention:
10 Completed Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients
Conditions: Head and Neck Cancer;   Lung Cancer
Intervention: Other: Assessments
11 Completed Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
12 Active, not recruiting Lung-MAP: AZD4547 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis
13 Active, not recruiting Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Rilotumumab
14 Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
15 Recruiting S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
16 Active, not recruiting S1400C Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Palbociclib
17 Active, not recruiting S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Taselisib
18 Active, not recruiting S1400A Lung-Map: MEDI4736 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
19 Recruiting Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate;   Drug: Volitinib
20 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Condition: Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.